Project Grant R01HL177113
Award Date
1/25/25
Completion Date
11/30/28
Dollars Obligated
$634K
Federal Agency
National Heart Lung and Blood Institute
Federal Grant Program
93.837
Assistance Type
Project Grant
Place of Performance
Missouri, USA
Similar Awards
This $1,088,500 Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) supports three independent research projects related to genetic and molecular mechanisms of heart disease. Project #1 aims to define microRNA targeting events and their biological relevance in the heart, as well as understand the clinical significance of genetic variants that alter cardiovascular microRNA functions. Project #2 seeks to...
The National Heart, Lung, and Blood Institute (NHLBI) awarded a $2,454,955 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to the Beckman Research Institute of the City of Hope. The grant titled "INTEGRATIVE ROLE OF RPS6KB1 IN PATHOLOGICAL CARDIAC REMODELING" aims to characterize the role of the RPS6KB1 protein in adaptive cardiac hypertrophy and heart failure progression, with a focus on understanding the regulation of RPS6KB1 through phosphorylation and...
The National Heart, Lung, and Blood Institute (NHLBI) awarded a $498,991.40 Project Grant under CFDA 93.837 - Cardiovascular Diseases Research to the University of Arkansas. The funding supports the development of microphysiological systems to study hypoxic cardiac injury and the molecular pathways activated in oxygen gradients, with the goal of obtaining a comprehensive understanding of the cardiac response to hypoxic injury. Key research activities include using engineering and pharmacological...
The National Heart, Lung, and Blood Institute (NHLBI) awarded a $2,158,878 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to the Rector & Visitors of the University of Virginia. The project aims to develop a novel approach to mitigate intimal hyperplasia, a common complication following angioplasty procedures. The key objectives are to: 1) Resolve the role of ALDH1A3, a metabolic regulator, in impairing endothelial cell function and promoting intimal...
The University of Arizona was awarded a $625,316 Project Grant from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) to investigate the role of RNA methylation and translational regulation in the oxidative stress response of heart failure. The research aims to elucidate how the YTHDF2 protein binds to methylated NRF2 mRNA to selectively induce its translation under oxidative stress, a process that may be impaired in end-stage heart failure. The...
The National Heart, Lung, and Blood Institute (NHLBI) awarded a $827,665 Project Grant under the Cardiovascular Diseases Research federal grant program (CFDA 93.837) to the New York Genome Center, Inc. (NYGC) to develop scalable methods for identifying causal genetic variants, relevant cell types, and target genes associated with cardiovascular disease. The grant aims to leverage population-scale, multi-ancestry genome-wide association studies to better understand the molecular and cellular...
The National Heart, Lung, and Blood Institute (NHLBI) awarded a $2,249,307 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to The Johns Hopkins University to conduct research on targeting the dysregulated maturation program in pluripotent-derived cardiomyocytes (PSC-CMs). The project aims to test the role of a conserved gene regulatory network in overcoming the premature arrest of PSC-CMs, which remain immature in phenotype and function, to improve their clinical...
This $125,250 Project Grant awarded by the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) will support a 2-year research project led by Dr. James Rhee at Massachusetts General Hospital (MGH). The project aims to study the role of the cytokine FAM3D in regulating cardiac fibrosis and inflammation in heart failure. Key objectives include rigorously investigating how FAM3D governs cardiac fibroblasts and lymphatic endothelial...
This federal Project Grant award, totaling $1,981,854.00, was provided by the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837). The funding will support research at Loyola University of Chicago's Health Sciences Campus to investigate the structural and functional basis of myocardial dysregulation in genetic cardiomyopathies. Specifically, the researchers will use advanced techniques like synchrotron X-ray diffraction and mass...
The National Heart, Lung, and Blood Institute (NHLBI), part of the National Institutes of Health (NIH), awarded a $517,475 Project Grant (CFDA 93.837 - Cardiovascular Diseases Research) to the University of South Florida (USF) to develop and evaluate P7C3-based small molecules for treating heart failure. The key objectives are to use medicinal chemistry, in vitro models, ex vivo cardiac tissue testing, and in vivo preclinical studies to identify 1-2 lead small molecule candidates that can...